HIV-1 protease inhibitors in development

Bibliography

• BOUCHER CAB, TERSMETTE M, LANGE J et al.: Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet (1990) 336:585–590.
   PubMed Web of Science ®Google Scholar
• KAHN JO, LAGAKOS SW, RICHMAN DD et al.: A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl. J. Med. (1992) 327:581–587.
   PubMed Web of Science ®Google Scholar
• D'AQUILA RT, HUGHES MD, JOHNSON VA et al.: Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann. Intern. Med. (1996) 124:1019-1030. A very interesting paper which demonstrated the efficacy of 3-drug convergent combination therapy in inhibiting HIV-1 in vivo.
   Google Scholar
• LARDER BA, DARBY G AND RICHMAN DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science (1989) 243:1731–1734.
   PubMed Web of Science ®Google Scholar
• ••Seminal paper which first described theemergence of drug resistance.
   Google Scholar
• LARDER BA AND KEMP SD: Multiple mutations in HIV-1 reverse transcriptaseconfer high-level resistance to zidovudine (AZT). Science (1989) 246:1155–1158.
   Google Scholar
• ••First demonstration of drug resistance pattern related to in situ mutagenesis procedures.
   Google Scholar
• RICHMAN DD, HAVLIR D, CORBEIL J et al.: Nevirapine resistance mutations of human immunodeficiency virus Type 1 selected during therapy. Vi rol. (1994) 68:1660–1666.
   Google Scholar
• •A paper which clearly describes the induction of nevirapine resistance following suboptimal therapy.
   Google Scholar
• RUSCONI S, DE PASQUALE MP, MILAZZO L et al.: Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1 infected patients in an ongoing open label trial. Antiviral The]: (1997) 2:41–48.
   Google Scholar
• ROBERTS NA, MARTIN JA, KINCHINGTON D et al.: Rational design of peptide-based HIV proteinase inhibitors. Science (1990) 248:358–361.
   PubMed Web of Science ®Google Scholar
• KEMPF DJ, MARSH KC, DENISSEN JF et al.: ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailabifity in humans. Proc. Nati Acad. Sci. USA (1995) 92:2484–2488.
   PubMed Web of Science ®Google Scholar
• VACCA JP, DORSEY BD, SCHLEIF WA etal.: L-735,524: an orally bioavailable human immunodeficiency virus Type 1 protease inhibitor. Proc. Nati Acad. Sci. USA (1994) 91:4096–4100.
   Google Scholar
• LONGER M, SHETTY B, ZAMANSKY I AND TYLE P: Preformulation studies of a novel HIV protease inhibitor, AG1343. Pharm. Sci. (1995) 84:1090–1093.
   PubMed Web of Science ®Google Scholar
• KIM EE, BAKER CT, DVVYER MD et al.: Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. (1995) 117:1181–1182.
   Web of Science ®Google Scholar
• COLLIER AC, COOMBS RW, SCHOENFELD DA et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl. J. Med. (1996) 334:1011–1017.
   PubMed Web of Science ®Google Scholar
• HAMMER SM, SQUIRES KE, HUGHES MD et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimiter or less. AIDS Clinical Trials Group 320 Study Team. N Engl. J. Med. (1997) 337:725–733.
   Google Scholar
• ••Fondarnental observation by a multicentrictrial which demonstrated the superiority of HAART versus 2-drug regimens.
   Google Scholar
• GULICK RM, MELLORS JW, HAVLIR D et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl. I Med. (1997) 337:734–739.
   PubMed Web of Science ®Google Scholar
• CAMERON DW, HEATH-CHIOZZI M, DANNER S et al.: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet (1998) 351:543–549.
   PubMed Web of Science ®Google Scholar
• ZHANG L, RAMRATNAM B, TENNER-RACZ P et al.: Quantifying residual HIV–1 replication in patients receiving combination antiretroviral therapy. N Engl. J. Med. (1999) 340:1605–1613.
   Google Scholar
• FURTADO MR, CALLAWAY DS, PHAIR JP et al.: Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Eng/. J. Med. (1999) 340:1614–1622.
   PubMed Web of Science ®Google Scholar
• DORNADULA G, ZHANG H, VANUITERT B et al: Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA (1999) 282: 1627-1632.
   Google Scholar
• COFFIN JM: HIV population dynamics invivo: implications for genetic variations, pathogenesis, and therapy. Science (1995) 267:483–489.
   PubMed Web of Science ®Google Scholar
• CONDRA JH, EMINI EA: Preventing HIV-1 drug resistance. Science & Medicine (1997) 4:14–23.
   Google Scholar
• CONDRA JH, SCHLEIF WA, BLAHY OM et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (1995) 374:569–571.
   PubMed Web of Science ®Google Scholar
• ••The first demonstration of PI cross-resistance.
   Google Scholar
• CONDRA JH, HOLDER DJ, SCHLEIF WA et al: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus Type 1 protease inhibitor. J. Viral. (1996) 70:8270–8276.
   PubMed Web of Science ®Google Scholar
• ••A seminal paper introducing the concept ofPI genetic barrier.
   Google Scholar
• WINTERS MA, SCHAPIRO JM, LAWRENCE J, MERIGAN TC: Human immunodeficiency virus Type 1 protease genotypes and in vitro protease inhibitors susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment., " Vim]. (1998) 72:5303–5306.
   Google Scholar
• DULIOUST A, PAOLOUS S, GUILLEMOT L, DELAVALLE A-M, BOUE F, CLAVEL F: Constrained evolution of human immunodeficiency virus Type 1 protease during sequential therapy with two distinct protease inhibitors. J. Virol (1999) 73:850–854.
   PubMed Web of Science ®Google Scholar
• •A paper which highlights the potential pharmacological pressure by a PI even after therapeutical shift to another.
   Google Scholar
• SCHAPIRO JM, WINTERS M, LAWRENCE J, MERIGAN TC: Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic meutations. AIDS (1999) 13:359–365.
   PubMed Web of Science ®Google Scholar
• ZOLOPA AR, SHAFER RW, WARFORD A et al.: HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann. Intern. Med. (1999)131:813–821.
   PubMed Web of Science ®Google Scholar
• HIRSCH MS, BRUN-VEZINET F, D'AQUILA RT et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA (2000) 283:2417–2426.
   Google Scholar
• ••An excellent summary which points out therationale of resistance testing in the clinical setting.
   Google Scholar
• CALL SA, SAAG MS, WESTFALL AO et al.: Phenotypic drug susceptibility testing predicts long-term virologic suppression beter than treatment history in patients with human immunodeficiencyvirus infection. J. Infect. Dis. (2001) 183:401–408.
   PubMed Web of Science ®Google Scholar
• ••A pivotal paper which relates the clinicaloutcome with the phenotypic resistance at baseline.
   Google Scholar
• MERRILL DP, MANION DJ, CHOU T-C, HIRSCH MS: Antagonism between human immunodeficiency virus Type 1 protease inhibitors indinavir and saquinavir in vitro. J. Infect. Dis. (1997)176:265–268.
   PubMed Web of Science ®Google Scholar
• CAMERON DW, JAPOUR AJ, XU Y et al:Ritonavir and saquinavir combination therapy for treatment of HIV. AIDS (1999)13:213–224.
   PubMed Web of Science ®Google Scholar
• ROCKSTROH JK, BERGMANN F, WIESEL W et al.: Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside cobination therapy in HIV-infected individuals. AIDS (2000)14: 1181–1185.
   PubMed Web of Science ®Google Scholar
• GALLANT JE, RAINES C, SUN E et al.: APhase II study on ritonavir/nelfinavir combination therapy: 48-week data. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA (1999). Abstract 393.
   Google Scholar
• SADLER BM, PILIERO PJ, PRESTON SL,YU L, STEIN DS: Pharmacokinetic (PK) drug-interaction between amprenavir (APV) and ritonavir (RTV) in HIV-seronegative subjects after multiple oral dosing. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA (2000). Abstract 77.
   Google Scholar
• MOYLE G, POZNIAK A, OPRAVIL M et al.: The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of protease inhibitor combinations in Europe.," Acquir. Immune Defic. Syndr. (2000) 23:128–137.
   Google Scholar
• SQUIRES K, RIDDLER S, HAVLIR D et al.: Co-administration of indinavir (my) 1200 mg with nelfinavir (NFV) 1250 mg in a twice daily regimen: preliminary safety PK activity. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA (1999). Abstract 364.
   Google Scholar
• NAVIA MA, FITZGERALD PMD, MCKEEVER BM et al.: Three-dimensional structure of aspartyl proetase from human immunodeficiency virus HIV-1. Nature (1989) 337:625–620.
   Google Scholar
• CONDRA JH: Virological and clinical implications of resistance to HIV-1 protease inhibitors. Drug Resist. Updates (1998) 1:292–299.
   PubMed Web of Science ®Google Scholar
• BODEN D, MARKOWITZ M: Resistance to human immunodeficiency virus Type 1 protease inhibitors. Antimicrob. Agents Chemother. (1998) 42:2775–2783.
   PubMed Web of Science ®Google Scholar
• SCHMIT J-C, RUIZ L, CLOTET B et al:Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS(1996) 10:995–999.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ M, MO H, KEMPF DJ et al.: Selection and analysis of human immunodeficiency virus Type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Vim]. (1995) 69:701–706.
   Web of Science ®Google Scholar
• TISDALE M, MYERS RE, MASCHERA B, PARRY NR, OLIVER NM, BLAIR ED: Cross-resistance analysis of human immunodeficiency virus Type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents. Chemother. (1995) 39:1704–1710.
   PubMed Web of Science ®Google Scholar
• MOLLA A, KORNEYEVA M, GAO Q et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med. (1996) 2:760–766.
   PubMed Web of Science ®Google Scholar
• •Evidence of ordered accumulation of PI-related mutations in vivo.
   Google Scholar
• MILLER V, HERTOGS K, DE BETHUNEM-P et al: Incidence of HIV-1 resistance and cross-resistance to protease inhibitors after indinavir failure: impact of subsequent ritonavir/saquinavir combination therapy. International Workshop and HIV Drug Resistance, Treatment Strategies and Eradication. International Medical Press Ltd. St Petersburg, Florida, USA. (1997). Abstract 81.
   Google Scholar
• POPPE SM, SLADE DE, CHONG K-T et al.: Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. (1997) 41:1058–1063.
   PubMed Web of Science ®Google Scholar
• •The first description of the new antiretroviral tipranavir.
   Google Scholar
• CHONG K-T, PAGANO PJ: In vitro combination of PNU-140690, a human immunodeficiency virus typel protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob. Agents Chemother. (1997) 41:2367–2373.
   PubMed Web of Science ®Google Scholar
• BALDWIN JR, BORIN MT, FERRY JJ et al.: Pharmacokinetics (PK) interaction between the HIV protease inhibitors tipranavir and ritonavir. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA (1999). Abstract 357.
   Google Scholar
• BORIN MT, WANG Y, SCHNECK DW, LI H, BREWER JE, DAENZER CL: Multiple-dose, safety, tolerance, and pharmacokinetics of the protease inhibitor PNU-140690 in healthy volunteers. 5th Conference on Retrovimses and Opportunistic Infections Chicago, IL, USA (1998). Abstract 648.
   Google Scholar
• WANG Y, FREIMUTH WW, DAENZER CL et al.: Safety and efficacy of PNU-140690, a new non-peptidic HIV protease inhibitor, and genotypic changes in patients in a Phase II study. 2nd International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy (1998). Abstract 5.
   Google Scholar
• WANG Y, DAENZER C, WOOD R et al: The safety, efficacy and viral dynamics analysis of tipranavir, a new-generation protease inhibitor, in a Phase II study in antiretroviral-Naive HIV-1-infected patients. 7th Conference on Retrovimses and Opportunistic Infections. San Francisco, California, USA (2000). Abstract 673.
   Google Scholar
• RUSCONI S, LA SETA CATAMANCIO S, CITTERIO P et al.: Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus Type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob. Agents Chemother. (2000) 44:1328–1332.
   Google Scholar
• LARDER BA, HERTOGS K, BLOOR S et al.: Tipranavir inhibits broadly proetase inhibitor-resistant HIV-1 clinical samples. A/DS(2000)14: 1943-1948.
   Google Scholar
• KEMP SD, SALIM M, FIELD N et al: Site- directed mutagenesis and M vitro drug selection studies have failed to reveal a consistent genotypic resistance pattern for tipranavir. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000) Abstract 2113.
   Google Scholar
• •A very interesting report based on unsuccessful attempt of selecting for tipranavir resistance in vitro.
   Google Scholar
• ROBINSON BS, RICCARDI KA, GONG YF et al.: BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. (2000) 44:2093–2099.
   PubMed Web of Science ®Google Scholar
• •The first description of the new antiretroviral BMS-232632.
   Google Scholar
• SANNE I, PILIERO P, WOOD R, KELLEHER T, CROSS A: Safety and antiviral efficacy of a once-daily HIV-1 protease inhibitor BMS-232632: 24 week result from a Phase II clinical trial. 40th Interscience Conference on Antimicrobial Agents and Agents and Chemotherapy Toronto, Canada (2000). Abstract 691.
   Google Scholar
• GONG YE ROBINSON BS, ROSE RE et al.: In vitro resistance profile of the human immunodeficiency virus Type 1 protease inhibitor BMS-232632. Antimicrob. Agents Chemother. (2000) 44:2391–2326.
   Google Scholar
• •An interesting paper described the emergence of specific mutations induced by BMS-232632.
   Google Scholar
• COLONNO RJ, HERTOGS K, LARDER BA, LIMOLI K, HEILCK-SNYDER G, PARKIN N: BMS-232632 sensitivity of a panel of HIV-1 clinical isolates resistant to one or more approved protease inhibitors. Antiviral The]: (2000) 5\(Suppl. 3): 7.
   Google Scholar
• PATICK AK, DURAN M, CAO Y et al: Genotypic and phenotypic characterization of human immunodeficiency virus Type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. (1998) 42:2637–2644.
   PubMed Web of Science ®Google Scholar
• ZIERMANN R, LIMOLI K, DAS K, ARNOLD E, PETROPOULOS CJ, PARKIN NT: A mutation in human immunodeficiency virus Type 1 protease, N885, that causes M vitro hypersensitivity to amprenavir. Viral. (2000) 74:4414–4419.
   PubMed Web of Science ®Google Scholar
• SMIDT ML, POTTS KE, TUCKER SP et al.: A mutation in human immunodeficiency virus Type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A. Antimicrob. Agents Chemother. (1997) 41:515–522.
   PubMed Web of Science ®Google Scholar
• TUCKER SP, STIEBEL TR JR, POTTS KE,SMIDT ML, BRYANT ML: Estimate of the frequency of human immunodeficiency virus Type 1 protease inhibitor resistance within unselected virus populations M vitro. Antimicrob. Agents Chemother. (1998) 42:478–480.
   PubMed Web of Science ®Google Scholar
• WANG LH, CHITTICK GE, PATANELLA JE AND MIRALLES GD: Effects of a novel HIV-1 protease inhibitor (PI), DMP450, on the pharmacokinetics (PK) of indinavir (IDV) and saquinavir (SQV). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000). Abstract 1647.
   Google Scholar
• SIERRA J, NINO S, VOLKOW P et al.: Preliminary profile of the antiviral activity, metabolic effects and safety of DMP-450, a novel cyclic urea protease inhibitor. Antiviral The]: (2000) 5\(Suppl. 3):6.
   Google Scholar
• CHITTICK GE, WANG LH, DEMASI RA, MIRALLES GD: Effects of a novel HIV-1 protease inhibitor (PI), DMP450, on cardiac tracing, serum lipids and glucose tolerance, as compared to indinavir (my). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000). Abstract 1648.
   Google Scholar
• ALA PJ, HUSTON EE, KLABE RM et al.: Molecular basis of HIV-1 protease drug drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry (1997) 36:1573–1580.
   PubMed Web of Science ®Google Scholar
• KALTENBACH III RF, TRAINOR G, GETMAN D et al: DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants. Antimicrob. Agents Chemother. (2001):3021–3028.
   PubMed Web of Science ®Google Scholar
• ERICKSON-VIITANEN S, KALTENBACH R, GETMAN D et al: DPC 681 and DPC 684: Resistance and cross-resistance profiles of second generation HIV protease inhibitors. 8th Conference on Retro viruses and Opportunistic Infections. Chicago, IL, USA (2001). Abstract 11.
   Google Scholar
• ERICKSON-VIITANEN S, KALTENBACH R, GETMAN D et al: DPC 681 and DPC 684: Selective inhibitors of the viral protease active against resistant variants of HIV. XIII International AIDS Conference. Durban, South Africa (2000). Abstract A532.
   Google Scholar
• BORISKIN Y: Clinical Implication of HIV Drug Resistance - Third European Symposium, Frankfurt, Germany (2001). IDdb Meeting Report.
   Google Scholar
• ERICKSON J, GULNIK S, SUVOROV Let al.: A femtomolar HIV-1 protease inhibitor with subnanomolar activity against multidrug resistant HIV-1 strains. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA (2001). Abstract 12.
   Google Scholar